Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)
16歳以上のシスジェンダー男性、トランスジェンダー女性、トランスジェンダー男性、およびジェンダー非バイナリーの人々におけるHIV暴露前予防のための、年2回の長期作用型レナカパビル皮下注射の有効性と安全性を評価する第3相、二重盲検、多施設、無作為化試験男性パートナーとセックスをし、HIV 感染のリスクがある年齢
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.
The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- UAB Sexual Health Research Clinic
-
-
California
-
Loma Linda、California、アメリカ、92354
- Loma Linda University Clinical Trial Center Clinic
-
Los Angeles、California、アメリカ、90069
- Mills Clinical Research
-
Los Angeles、California、アメリカ、90036
- Ruane Clinical Research Group Inc.
-
Los Angeles、California、アメリカ、90038
- UCLA CBAM Vine Street Clinic
-
Los Angeles、California、アメリカ、90059
- Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
-
Los Angeles、California、アメリカ、90502
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Palm Springs、California、アメリカ、92262
- BIOS Clinical Research
-
San Diego、California、アメリカ、92103
- UCSD Anti Viral Research Center
-
San Francisco、California、アメリカ、94102
- Optimus Medical Group
-
San Francisco、California、アメリカ、94102
- Bridge HIV at the San Francisco Department of Public Health
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Clinical and Translational Research Centers (CTRC)
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- Yale University, School of Medicine
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20009
- Whitman-Walker Institute Inc.
-
Washington D.C.、District of Columbia、アメリカ、20017
- Washington Health Institute
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33308
- Therafirst Medical Center
-
Fort Lauderdale、Florida、アメリカ、33316
- Gary Richmond, MD, PA
-
Ft. Pierce、Florida、アメリカ、34982
- Midway Immunology & Research Center, LLC
-
Jacksonville、Florida、アメリカ、32207
- CAN Community Health Clinic
-
Miami、Florida、アメリカ、33136
- University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
-
Miami Gardens、Florida、アメリカ、33055
- CAN Community Health
-
Orlando、Florida、アメリカ、32803
- Orlando Immunology Center
-
Sarasota、Florida、アメリカ、34237
- CAN Community Health
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30303
- Emory University
-
Atlanta、Georgia、アメリカ、30308
- Emory University Hospital Midtown Infectious Disease Clinic
-
Atlanta、Georgia、アメリカ、30030
- The Hope Clinic at Emory University
-
-
Illinois
-
Chicago、Illinois、アメリカ、60613
- Howard Brown Health Center
-
Chicago、Illinois、アメリカ、60612
- RMR Core Center
-
Chicago、Illinois、アメリカ、60612
- University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University Infectious Diseases Research
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40503
- Baptist Health Lexington
-
Louisville、Kentucky、アメリカ、40241
- Norton Infectious Disease Specialists
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70119
- LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University School of Medicine
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- The Fenway Institute
-
-
Michigan
-
Berkley、Michigan、アメリカ、48072
- Be Well Medical Center
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39202
- Open Arms Healthcare Center
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- KC CARE Health Center
-
-
New Jersey
-
Newark、New Jersey、アメリカ、07102
- St. Michael's Medical Center
-
Somers Point、New Jersey、アメリカ、08244
- South Jersey Infectious Disease
-
-
New York
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
-
Greensboro、North Carolina、アメリカ、27401
- Cone Health/Regional Center for Infectious Disease Research Center
-
Winston-Salem、North Carolina、アメリカ、27103
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267
- University of Cincinnati
-
Columbus、Ohio、アメリカ、43210
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Penn Prevention Unit
-
Philadelphia、Pennsylvania、アメリカ、19107
- Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina, Infectious Disease Clinic
-
Columbia、South Carolina、アメリカ、29203
- Prisma Health-Midlands Clinical Research Unit
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Internal Medicine Clinic
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38105
- St Jude Children's Research Hospital
-
Memphis、Tennessee、アメリカ、38103
- Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
-
Nashville、Tennessee、アメリカ、37208
- Meharry Medical College Clinical and Transitional Research Center
-
-
Texas
-
Austin、Texas、アメリカ、78705
- Central Texas Clinical Research
-
El Paso、Texas、アメリカ、79915
- Centro San Vincente
-
Houston、Texas、アメリカ、77098
- The Crofoot Research Center, INC
-
Houston、Texas、アメリカ、77009
- UT Health Science Center at Houston
-
-
Washington
-
Seattle、Washington、アメリカ、98104
- Ofiice of Dr. Peter Shalit, MD
-
-
-
-
-
Buenos Aires、アルゼンチン、1072
- Hospital General de Agudos JM Ramos Mejia
-
Buenos Aires、アルゼンチン、B7600
- Instituto de Investigaciones Clinicas Mar del Plata
-
Buenos Aires、アルゼンチン、1202
- Fundacion Huesped
-
-
-
-
-
Bangkok、タイ、10330
- King Chulalongkorn Memorial Hospital
-
Bangkok、タイ、10400
- Ramathibodi Hospital, Mahidol University
-
Bangkok、タイ、10330
- Institute of HIV Research and Innovation
-
Bangkok、タイ、10330
- The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
-
Chiang Mai、タイ、50200
- Research Institute for Health Sciences, Chiang Mai University
-
Khon Kaen、タイ、40002
- Srinagarind Hospital, Khon Kaen University
-
Nonthaburi、タイ、11000
- Bamrasnaradura Infectious Disease Institute
-
-
-
-
-
Belo Horizonte - MG、ブラジル、30130-100
- Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
-
Canela-Salvador、ブラジル、40110-060
- Fundação Bahiana de Infectologia
-
Manauas、ブラジル、69040-000
- Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
-
Nova Iguaçu、ブラジル、26030-380
- Hospital General de Nova Iguaçu - HGNI
-
Porto Alegre、ブラジル、RS 91350 200
- Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
-
Rio de Janeiro、ブラジル、21040-360
- Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
-
São Paulo、ブラジル、01246-903
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
-
São Paulo、ブラジル、04121-000
- Centro de Referência e Treinamento DST/AIDS
-
São Paulo、ブラジル、06519-332
- Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
-
-
-
-
PR
-
San Juan、PR、プエルトリコ、00717
- Ararat Research Center
-
San Juan、PR、プエルトリコ、00909
- Centro Ararat- San Juan
-
-
-
-
-
Barranco、ペルー、15063
- Asociacion Civil Impacta Salud y Educacion - Sede Barranco
-
Callao、ペルー、7006
- Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
-
Iquitos、ペルー
- Asociacion Civil Selva Amazonica
-
Lima、ペルー、15001
- Via Libre
-
Lima、ペルー、15088
- Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
-
-
-
-
-
Guadalajara C.P.、メキシコ、44160
- Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
-
-
-
-
-
Cape Town、南アフリカ、7925
- Desmond Tutu Health Foundation
-
Johannesburg、南アフリカ、2038
- Wits Reproductive Health and HIV Institute (Wits RHI)
-
Pretoria、南アフリカ、87
- The Aurum Institute: Pretoria Clinical Research Centre
-
Soshanguvhe、南アフリカ、0152
- Setshaba Research Centre
-
Tembisa、南アフリカ、1632
- The Aurum Institute Tembisa CRC, Clinic 4
-
Vincent、南アフリカ、5217
- FPD-DTHF Ndevana Commuity Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
Incidence Phase
-
CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
-
HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.
-
Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:
- Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
- History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
- Self-reported use of stimulants with sex in the last 12 weeks.
Randomized Phase
- Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
- Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).
Key Exclusion Criteria:
Incidence Phase
- Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
- Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.
Randomized Phase
- Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
- Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF
Participants will receive the following for up to approximately 52 weeks:
Participants will receive oral LEN if SC injections are not available. |
Tablets administered orally without regard to food
他の名前:
Administered via SC injections
他の名前:
Tablets administered orally |
|
実験的:Randomized Blinded Phase: Placebo LEN + F/TDF
Participants will receive the following for up to approximately 52 weeks:
Participants will receive oral LEN placebo if SC injections are not available. |
Tablets administered orally
他の名前:
Administered via SC injections Tablets administered orally |
|
実験的:LEN Open-Label Extension (OLE) Phase
Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase. Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days). Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2. All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first. After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit. |
Tablets administered orally without regard to food
他の名前:
Administered via SC injections
他の名前:
|
|
実験的:Pharmacokinetic (PK) Tail Phase
Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days). Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit. |
Tablets administered orally
他の名前:
F/TAF tablets administered orally once daily
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
時間枠:Incidence Phase Screening Visit (Day 1)
|
bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was > 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit:
|
Incidence Phase Screening Visit (Day 1)
|
|
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
時間枠:Up to 149 weeks
|
HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1. |
Up to 149 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
時間枠:Up to 149 weeks
|
HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. |
Up to 149 weeks
|
|
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
時間枠:Up to 149 weeks
|
A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2. |
Up to 149 weeks
|
|
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
時間枠:First dose date up to 184 weeks
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. |
First dose date up to 184 weeks
|
|
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
時間枠:First dose date up to 184 weeks
|
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off. |
First dose date up to 184 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Gilead Study Director、Gilead Sciences
出版物と役立つリンク
一般刊行物
- Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2). Presented at: HIV Drug Therapy Glasgow; November 10-13, 2024; Glasgow, United Kingdom.
- Kelley CF, Acevedo-Quinones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sanchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27.
- Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLoS One. 2022 Jun 3;17(6):e0267780. doi: 10.1371/journal.pone.0267780. eCollection 2022.
- Cantos Lucio VD, Mngadi K, Supparatpinyo K, et al. From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI 2026); February 22-25, 2026; Denver, CO. Abstract 129.
- Kwan TH, Chan DPC, Lee SS. Utilisation of HIV pre-exposure prophylaxis and preferences of alternative long-acting modalities among men who have sex with men in Hong kong: a cross-sectional study. BMC Public Health. 2025 Dec 26;26(1):361. doi: 10.1186/s12889-025-26025-5.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- GS-US-528-9023
- DOH-27-102021-6681 (その他の識別子:South African National Clinical Trial Registry)
- 2023 (米国 NIH グラント/契約)
- 2023-001025-23 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。